ECSP099681A - Formas sólidas de (e)-1-(4-((1r,2s,3r)-1,2,3,4-tetrahidroxibutil)-1h-imidazol-2-il) etanona oxima - Google Patents

Formas sólidas de (e)-1-(4-((1r,2s,3r)-1,2,3,4-tetrahidroxibutil)-1h-imidazol-2-il) etanona oxima

Info

Publication number
ECSP099681A
ECSP099681A EC2009009681A ECSP099681A ECSP099681A EC SP099681 A ECSP099681 A EC SP099681A EC 2009009681 A EC2009009681 A EC 2009009681A EC SP099681 A ECSP099681 A EC SP099681A EC SP099681 A ECSP099681 A EC SP099681A
Authority
EC
Ecuador
Prior art keywords
imidazol
tetrahydroxibute
etanona
oxima
solid forms
Prior art date
Application number
EC2009009681A
Other languages
English (en)
Inventor
Wenxue Wu
Haiming Zhang
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of ECSP099681A publication Critical patent/ECSP099681A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen formas sólidas amorfas y cristalinas de (E)-M-(4-((1R,2S,3R)-1,2,3,4-tetrahidroxibutil)-1H-imidazol-2-il)-etanona oxima. Estas formas sólidas específicas se pueden utilizar como moduladores fosfato de esfingosita-1 para tratar enfermedades autoinmunes e inflamatorias.
EC2009009681A 2007-04-12 2009-10-07 Formas sólidas de (e)-1-(4-((1r,2s,3r)-1,2,3,4-tetrahidroxibutil)-1h-imidazol-2-il) etanona oxima ECSP099681A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92303707P 2007-04-12 2007-04-12

Publications (1)

Publication Number Publication Date
ECSP099681A true ECSP099681A (es) 2009-12-28

Family

ID=39639233

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009681A ECSP099681A (es) 2007-04-12 2009-10-07 Formas sólidas de (e)-1-(4-((1r,2s,3r)-1,2,3,4-tetrahidroxibutil)-1h-imidazol-2-il) etanona oxima

Country Status (22)

Country Link
US (2) US20080275099A1 (es)
EP (1) EP2139865B1 (es)
JP (1) JP5496080B2 (es)
KR (1) KR20100015464A (es)
CN (1) CN101284818B (es)
AR (1) AR065979A1 (es)
AU (1) AU2008240255B2 (es)
BR (1) BRPI0810197A2 (es)
CA (1) CA2683963A1 (es)
CL (1) CL2008001043A1 (es)
CO (1) CO6230981A2 (es)
EA (1) EA017042B1 (es)
EC (1) ECSP099681A (es)
ES (1) ES2453543T3 (es)
IL (1) IL201037A (es)
MX (1) MX2009010904A (es)
NZ (1) NZ579689A (es)
PE (1) PE20090072A1 (es)
TW (1) TWI412362B (es)
UY (1) UY31012A1 (es)
WO (1) WO2008128045A1 (es)
ZA (1) ZA200906493B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
TW200848029A (en) 2007-03-01 2008-12-16 Lexicon Pharmaceuticals Inc Heterocyclic compounds, compositions comprising them and methods of their use
AR065980A1 (es) 2007-04-12 2009-07-15 Lexicon Pharmaceuticals Inc Metodos para preparar compuestos basados en imidazol
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
EP2315765B1 (en) * 2008-06-18 2012-12-19 Lexicon Pharmaceuticals, Inc. Solid forms of (1r,2s,3r)-1-(2-(isoxazol-3-yl)-1h-imidazol-4-yl)butane-1,2,3,4-tetraol and methods of their use
US8653126B2 (en) 2010-02-18 2014-02-18 Daiichi Sankyo Company, Limited Imidazole derivative
JP5757635B2 (ja) 2010-06-28 2015-07-29 第一三共株式会社 培養細胞を用いたｓ１ｐリアーゼ阻害剤のスクリーニング方法
TW201311710A (zh) 2011-06-28 2013-03-16 Daiichi Sankyo Co Ltd 磷酸酯衍生物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567194A (en) * 1983-03-10 1986-01-28 The Coca-Cola Company 2-Acylimidazole compounds, their synthesis and use as medicinal agents
ZA974811B (en) * 1996-05-31 1997-12-30 Univ Wollongong Novel therapeutic compounds.
CN101395141A (zh) * 2006-02-24 2009-03-25 莱西肯医药有限公司 咪唑基化合物，包含其的组合物和它们的使用方法
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
AR065980A1 (es) * 2007-04-12 2009-07-15 Lexicon Pharmaceuticals Inc Metodos para preparar compuestos basados en imidazol

Also Published As

Publication number Publication date
NZ579689A (en) 2011-10-28
JP2010523707A (ja) 2010-07-15
UY31012A1 (es) 2008-09-02
US8658682B2 (en) 2014-02-25
CO6230981A2 (es) 2010-12-20
JP5496080B2 (ja) 2014-05-21
TW200848027A (en) 2008-12-16
AR065979A1 (es) 2009-07-15
CN101284818B (zh) 2012-10-03
AU2008240255A1 (en) 2008-10-23
HK1124851A1 (en) 2009-07-24
MX2009010904A (es) 2009-10-26
EA017042B1 (ru) 2012-09-28
US20090298901A1 (en) 2009-12-03
WO2008128045A8 (en) 2010-01-21
WO2008128045A1 (en) 2008-10-23
ZA200906493B (en) 2010-11-24
PE20090072A1 (es) 2009-02-18
KR20100015464A (ko) 2010-02-12
CA2683963A1 (en) 2008-10-23
IL201037A0 (en) 2010-05-17
EA200970940A1 (ru) 2010-02-26
US20080275099A1 (en) 2008-11-06
ES2453543T3 (es) 2014-04-08
IL201037A (en) 2015-08-31
AU2008240255B2 (en) 2013-07-04
TWI412362B (zh) 2013-10-21
EP2139865B1 (en) 2014-01-01
CL2008001043A1 (es) 2008-09-26
BRPI0810197A2 (pt) 2014-12-30
EP2139865A1 (en) 2010-01-06
CN101284818A (zh) 2008-10-15

Similar Documents

Publication Publication Date Title
CR11284A (es) Sulfonamidas como moduladores de trpm8
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
TN2009000388A1 (en) 3-imidazolyl-indoles for the treatment of proliferative diseases
SV2010003593A (es) Nuevos herbicidas
MX347804B (es) Formas solidas de (r)-1(2,2-difluorobenzo[d] [1,3]dioxol-5-il)-n-( 1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il) -1h-indol-5-il) ciclopropanocarboxamida.
DK2620493T3 (da) Mesenkymale stamceller til behandling af CNS-sygdomme
CR20110043A (es) Mezclas fungicidas que comprenden 1-metilpirazol-4-ilcarboxanilidas sustituidas
MA32562B1 (fr) Composes organiques pour la cicatrisation de lesion
EP2350129A4 (en) PD1 Antagonist Compositions and Methods for their Use
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
PL3190128T3 (pl) Kompozycje i sposoby leczenia zaburzeń, w których pośredniczy IgE
MX373157B (es) Metodos de extincion mejorados para la inactivacion de patogenos en globulos rojos.
EA201071320A1 (ru) Активаторы глюкокиназы
MX389288B (es) Compuestos heterocíclicos útiles como inhibidores de proteína cinasa-1 dependiente de 3-fosfoinositido (pdk1).
EA200970940A1 (ru) Твердые формы (е)-1-(4-((1r,2s,3r)-1,2,3,4-тетрагидроксибутил)-1h-имидазол-2-ил)этаноноксима
EA201070447A1 (ru) Способ обработки волос
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
PA8796001A1 (es) Moduladores tieno- y furo-pirimidina del receptor de histamina h4
EA200970818A1 (ru) Гетероциклические соединения, содержащие их композиции и способы их применения
NI201100096A (es) Lactamas como inhibidores de beta secretasa.
CR20110660A (es) Mezclas fungicidas
AR065714A1 (es) Sal clorhidrato de 5- (3-( 3- hidroxifenoxi ) azetidin- 1 - il ) - 5 - metil - 2, 2 - difenilhexanamida
GT200900045A (es) Sales de bencimidazolilo piridilo eteres y las formulaciones del mismo
CR20130106A (es) Nuevos moduladores de trpv3